Leqembi® Achieves Significant Sales Growth in Third Quarter of 2026

Leqembi® Sales Surge in Q3 2026

In the latest financial announcement from Eisai, the global sales total for Leqembi®, a leading treatment for Alzheimer’s disease, has reached an impressive 32.2 billion yen in the third quarter of 2026. This notable figure reflects the increasing acceptance and demand for the drug, underscoring its effectiveness in managing early Alzheimer's disease symptoms.

As a result of this surge in sales, BioArctic AB, the Swedish biopharma company that developed Leqembi® in collaboration with Eisai, is set to earn royalties amounting to SEK 203.8 million. This is a remarkable rise of approximately 74% compared to the same quarter in the previous year, 2025, signaling a strong market performance for both BioArctic and Eisai.

The announcement, made on October 28, 2026, coincides with Biogen's report for the same quarter, solidifying the partnership's financial success. BioArctic is expected to publicly share its detailed Q3 results on November 25, 2026. Such promising performance is critical in the context of the increasing number of Alzheimer's patients globally and the urgent need for effective treatments.

About Leqembi®

Leqembi® (lecanemab) is a humanized monoclonal antibody that targets both aggregated soluble and insoluble amyloid-beta forms. It has achieved regulatory approval in 53 countries, with ongoing reviews in six others. This treatment regimen began with bi-weekly sessions for the first 18 months, followed by a maintenance dose every four weeks, now approved in several nations including the US, Japan, and the UK.

In the US, Leqembi is also available for subcutaneous administration through an autoinjector, providing more flexible treatment options for patients. The drug’s approval in countries such as China and Japan for subcutaneous initiation treatment underscores its extensive reach and acceptance.

Over the years, Eisai has been conducting ongoing clinical trials to further validate Leqembi's efficacy. The AHEAD 3-45 study, focusing on preclinical Alzheimer's patients, is currently in its fourth year and is essential for understanding the long-term benefits of lecanemab. This study is part of a collaboration among Eisai, Biogen, and the Alzheimer's Clinical Trial Consortium, showcasing a robust public-private partnership aimed at tackling dementia-related conditions.

Collaboration Between BioArctic and Eisai

BioArctic’s strategic collaboration with Eisai began in 2005, resulting in the signing of several agreements that paved the way for the development and commercialization of treatments like Leqembi. Notably, the agreement for the lecanemab antibody came in 2007, followed by further development arrangements in 2015, illustrating the long-term commitment both companies have towards combating Alzheimer’s disease.

BioArctic retains commercial rights in the Nordic region, ensuring a steady revenue stream without bearing development costs. The relationship continues to thrive as both companies explore innovative avenues for treatment and strive to improve quality of life for Alzheimer’s patients.

In addition to Leqembi, BioArctic maintains an active research portfolio targeting diseases such as Parkinson’s and ALS, utilizing their proprietary BrainTransporter™ technology that aims to enhance drug effectiveness by overcoming the blood-brain barrier.

Conclusion

The robust sales figures for Leqembi® in Q3 of 2026 illustrate not only the critical demand for effective Alzheimer's treatments but also the success of the enduring partnership between BioArctic and Eisai. As research progresses and more patients access this life-changing drug, the potential for growth and impact in the field of neurodegenerative disease treatment remains significant.